sel-212
selecta biosciences
['dissolve ii', 'dissolve i']
#eular2023 #lb0002 potential option for refractory gout? data from phase 3 rct showed sel-212 (pegylated uricase, co-administered with nanoencapsulated rapamycin) met primary endpoint (sua &lt;6 mg/dl for 80% of the time) vs pbo at 6mths. low infusion reaction (3.4%) 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏